Navigation Links
MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
Date:9/11/2007

VANCOUVER, and SAN DIEGO, Sept. 11 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, reports financial results for the three months ended July 31, 2007 and an update on its programs.

UPDATE ON DRUG DEVELOPMENT PROGRAMS

Omiganan 1% gel (Omigard(TM)/CPI-226/MX-226; topical cationic peptide; prevention of catheter-related infections): A pivotal Phase III study is in progress in the United States under a Special Protocol Assessment (SPA) agreement with the US FDA and in Europe. This confirmatory Phase III trial is a randomized, Evaluation Committee-blinded study to assess the effectiveness of Omigard(TM) vs. 10% povidone-iodine for the prevention of central venous catheter-related infections. This ongoing trial is known as the Central Line Infection Reduction Study, or CLIRS trial.

On July 30, 2007 Cadence Pharmaceuticals, our North American and European development and commercialization partner for Omigard(TM), announced that the FDA had agreed with their plan to increase the number of patients to be enrolled in CLIRS trial from 1,250 to 1,850. Cadence also announced that in June 2007 it completed enrollment of the original target of 1,250 patients in this clinical trial. Cadence expects they will complete enrollment of the new goal of 1,850 patients in the second quarter of 2008. If the results of the CLIRS trial are positive, Cadence expects to submit an NDA for omiganan 1% gel in the first half of 2009.

Celgosivir (MX-3253; oral a-glucosidase I inhibitor; treatment of chronic hepatitis C virus infections): Final top-line results of a Phase II combination study in non-responder and partial responder patients were announced April 11, 2007, demonstrating proof-of-concept and evidence of clinical benefit when adding celgosivir to the current standard-of-care HCV therapy (pegylated interferon plus ribavirin) as compared to the active control treatment (standard-of-care
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... ... company, launched “Cannavoices,” an unprecedented digital video and broadcast initiative. Produced by filmmakers, ... most dynamic collection of legal medical cannabis stories ever assembled. , Cannavoices ...
(Date:6/29/2015)... , June 29, 2015 BioNano Genomics, Inc., ... top research institutes, announced today that a collaboration led ... resulted in the creation of the first comprehensive analysis ... DNA molecule methods for sequencing and genome mapping. This ... the comprehensive analysis of the contiguous diploid human genome ...
(Date:6/29/2015)... ... June 29, 2015 , ... The StampedeCon 2015 Big ... the fourth year in a row, will bring top technology professionals to St. Louis. ... the intersection of data and technology. The event is proudly sponsored by DataStax, Cisco, ...
(Date:6/26/2015)... Kan. , June 26, 2015 /PRNewswire/ ... PETX ), a pet therapeutics company focused ... innovative biopharmaceutical products for companion animals, today ... effectiveness study of capromorelin (AT-002), the company,s ... Capromorelin is a small molecule that mimics ...
Breaking Biology Technology:Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 2BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 3StampedeCon Announces 2015 Agenda 2StampedeCon Announces 2015 Agenda 3Aratana Therapeutics Announces Positive Pivotal Results for AT-002 2Aratana Therapeutics Announces Positive Pivotal Results for AT-002 3Aratana Therapeutics Announces Positive Pivotal Results for AT-002 4Aratana Therapeutics Announces Positive Pivotal Results for AT-002 5
... ,, HARBIN, China , ... One Medical,Inc. ("China Sky One Medical" or "the ... pharmaceutical company producing over-the-counter drugs in, the People,s ... its Tian Long,Pharmaceutical Company ("Tian Long") subsidiary successfully ...
... May 27 /PRNewswire-Asia-FirstCall/ -- Concord Medical Services,Holdings Limited ("Concord ... the largest network of radiotherapy and diagnostic imaging centers,in China ... March 31, 2010 (1). , , First ... in the first quarter of 2010 were RMB76.2 million, ...
... 27, 2010 , , , ... - New Trial Results on ExoSeal(TM) Vascular Closure Device Support its,Clinical Safety* and Efficacy ... Cordis Corporation, a worldwide ... Vascular Closure Device. ExoSeal(TM) incorporates a number of new,advances in technology and simplicity of ...
Cached Biology Technology:China Sky One Medical Receives GMP Re-Certification 2China Sky One Medical Receives GMP Re-Certification 3Concord Medical Announces First Quarter 2010 Financial Results 2Concord Medical Announces First Quarter 2010 Financial Results 3Concord Medical Announces First Quarter 2010 Financial Results 4Concord Medical Announces First Quarter 2010 Financial Results 5Concord Medical Announces First Quarter 2010 Financial Results 6Concord Medical Announces First Quarter 2010 Financial Results 7Concord Medical Announces First Quarter 2010 Financial Results 8Concord Medical Announces First Quarter 2010 Financial Results 9Concord Medical Announces First Quarter 2010 Financial Results 10Concord Medical Announces First Quarter 2010 Financial Results 11Concord Medical Announces First Quarter 2010 Financial Results 12Concord Medical Announces First Quarter 2010 Financial Results 13Concord Medical Announces First Quarter 2010 Financial Results 14Concord Medical Announces First Quarter 2010 Financial Results 15CORDIS Launches ExoSeal(TM) Vascular Closure Device 2CORDIS Launches ExoSeal(TM) Vascular Closure Device 3CORDIS Launches ExoSeal(TM) Vascular Closure Device 4
(Date:6/24/2015)... 2015 The biologics safety testing market is ... the market include growth of the pharmaceutical and biological ... Over the years, the number of drug approvals in ... the FDA approved 225 drug applications and Health Canada ... Europe accounted for 3,822 of the pharmaceutical ...
(Date:6/23/2015)... , June 23, 2015   MedNet Solutions ... supports the entire spectrum of clinical research, is ... ™ , the company,s intuitive, flexible and ... a Silver 2015 Stevie® Award by the ... & Services Website category.  The American Business Awards ...
(Date:6/18/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market announces that its Wocket® smart wallet will be ... Mark", scheduled to air on WABC Radio (am770) in ... The broadcast air- time for the extensive ... NXT-ID, Inc.,s CEO Gino Pereira will be discussing ...
Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3
... cancer researchers Robert Weinberg, a Founding Member of Whitehead ... for Experimental Cancer Research (ISREC) have updated their seminal ... study of cancer and the development of therapeutics for ... their original work, which codified the traits that all ...
... North Grafton, Mass., March 16, 2011 The ... varies as widely as owner,s perceptions about them, according ... at the Cummings School of Veterinary Medicine at Tufts ... nutritional needsboth for humans and petschange with aging, the ...
... MaxID, a leading provider of mobile identity solutions and ... in India are pleased to announce that they have teamed ... and software driven by the efforts of the Unique Identification ... is extremely fortunate to be working with I.D. Solutions in ...
Cached Biology News:Whitehead scientist helps revisit 'Hallmarks of Cancer' 2Whitehead scientist helps revisit 'Hallmarks of Cancer' 3Wide variety in nutritional content found in 'senior' dog foods 2Wide variety in nutritional content found in 'senior' dog foods 3MaxID and I.D. Solutions Team Up to Address the Indian Identity Market 2MaxID and I.D. Solutions Team Up to Address the Indian Identity Market 3